EDAP’s HIFU Progress Is Obscured By The Pandemic, But It’s Real
Favorable changes in market acceptance and reimbursement for the FocalOne have been obscured by pandemic headwinds.
However, the company continues at breakeven because of strong growth in its distribution business, the result of a fantastic strategic deal with Exact Imaging.
While pandemic headwinds could blow a little longer, sooner or later the lid will be blown off of FocalOne installation growth and as long as the distribution business.
As long as the distribution business keeps on delivering, the wait isn’t problematic and the shares are already attractive at $6 and change.